Welcome!
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
In Seattle, we just had an evening program for lung cancer awareness that included issues in lung cancer largely focused on rectifying the disparity in lung cancer funding and awareness compared with other cancers, but also on tobacco control and screening. One of the talks was by a pulmonologist colleague from the University of Washington, Dr. Jason Chien, who highlighted several notable points on smoking patterns and how they are related to risk of lung cancer.
The first point is that while we talk a lot about never-smokers with lung cancer, tobacco is still by far the most important risk factor contributing to lung cancer. Here's a list of other variables, which pale in their impact compared to tobacco ("relative risk" means the multiplier compared to someone without a risk factor, so a relative risk of 2 means that a person with that exposure has twice the risk of somoene without it):
Tragically, unlike most or perhaps all other deadly diseases in the world, lung cancer has a major industry promoting the exposure to this deadly risk factor:
Despite this force, smoking patterns have been declining over time, particularly in states in which there are stronger smoking cessation efforts, and less so in states that rely on tobacco as a leading component of their economy. Overall, it's about 20% overall and gradually declining over time:
This is largely because many people are quitting successfully, but as a side effect, there are growing ranks of ex-smokers in the US, now approaching 50 million. Fortunately, this has been associated with a significant decline in lung cancer deaths among men, and the start of a decline in lung cancer deaths now among women, who overall took up smoking later than men and have been a little slower to quit -- we hope the curves for women follow the decline seen in men over the next few decades:
Next, we'll turn to how much and how quickly the risk of smoking declines after a person quits smoking.
Please feel free to offer comments and raise questions in our
discussion forums.
Bispecifics, or bispecific antibodies, are advanced immunotherapy drugs engineered to have two binding sites, allowing them to latch onto two different targets simultaneously, like a cancer cell and a T-cell, effectively...
The prefix “oligo–” means few. Oligometastatic (at diagnosis) Oligoprogression (during treatment)
There will be a discussion, “Studies in Oligometastatic NSCLC: Current Data and Definitions,” which will focus on what we...
Radiation therapy is primarily a localized treatment, meaning it precisely targets a specific tumor or area of the body, unlike systemic treatments (like chemotherapy) that affect the whole body.
The...
Biomarkers are genetic mutations (like EGFR, ALK, KRAS, BRAF) or protein levels (like PD-L1) in tumor cells that help guide personalized treatment, especially NSCLC, directing patients to targeted therapies or immunotherapies...
Hi Stan! So good to hear from you. I'm sorry for the late response. I too have been out of town with family and missed your post, probably because I was...
It is so good to hear from you! And I am so happy to hear that your holidays have been good and that you are doing well. It sounds like your...
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components: